Hostname: page-component-6898cfcb55-th4rj Total loading time: 0 Render date: 2026-11-12T00:46:34.974Z Has data issue: false hasContentIssue false
  • English
  • Français

Improving fluoroquinolone use in the outpatient setting using a patient safety initiative

Published online by Cambridge University Press:  17 August 2018

Kazuaki JindaiOpen the ORCID record for Kazuaki Jindai[Opens in a new window],
Michihiko GotoOpen the ORCID record for Michihiko Goto[Opens in a new window],
Kimberly MacKay,
Graeme N. Forrest,
Jackson Musuuza,
Nasia Safdar and
Christopher D. Pfeiffer
Kazuaki Jindai*
Affiliation:
School of Public Health, Oregon Health and Science University, Portland, OregoDepartment of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon
Michihiko Goto
Affiliation:
Iowa City Veterans Affairs Medical Center, Iowa City, IowaDivision of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa
Kimberly MacKay
Affiliation:
Department of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon
Graeme N. Forrest
Affiliation:
Department of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, OregonDivision of Infectious Disease, Department of Medicine, Oregon Health and Science University, Portland, Oregon
Jackson Musuuza
Affiliation:
Institute of Clinical and Translational Research, University of Wisconsin, Madison, Wisconsin
Nasia Safdar
Affiliation:
Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WisconsinThe William S. Middleton VA Medical Center, Madison, Wisconsin
Christopher D. Pfeiffer
Affiliation:
Department of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, OregonDivision of Infectious Disease, Department of Medicine, Oregon Health and Science University, Portland, Oregon
*
*Author for correspondence: Kazuaki Jindai, MD, MPH, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-8916 Japan. E-mail: jindaik@who.int
Rights & Permissions [Opens in a new window]

Abstract

We analyzed the impact of a fluoroquinolone patient safety initiative on the weekly fluoroquinolone prescription rate in Veterans Affairs community-based outpatient clinics. We observed a significant initial but unsustained reduction. Such an initiative can function as an antimicrobial stewardship intervention; however, strategies to promote sustainability should be explored.

Information

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 9 , September 2018, pp. 1108 - 1111
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Fluoroquinolones (FQs) are broad-spectrum antibiotics that are frequently overprescribed in the outpatient settingReference Kabbani, Hersh, Shapiro, Fleming-Dutra, Pavia and Hicks 1 and have been associated the development of multidrug-resistant infections,Reference Stewardson, Vervoort and Adriaenssens 2 Clostridium difficile infections,Reference Dingle, Didelot and Quan 3 and adverse drug reactions such as tendon rupture. 4 In July 2014, in response to the recommendation by the Office of Inspector General at the Department of Veterans Affairs (VA), 5 the VA Portland Healthcare System (VAPORHCS) implemented an outpatient safety initiative via a mandatory FQ order checklist in the electronic health record (EHR).

Although studies have described interventions to promote judicious outpatient antibiotic prescribing,Reference Meeker, Linder and Fox 6 , Reference Persell, Doctor and Friedberg 7 a paucity of data exist on how a patient safety initiative using an EHR-embedded checklist could impact antibiotic prescriptions. Using a retrospective interrupted time-series analysis, we tested the hypothesis that this FQ patient safety initiative would sustainably reduce oral FQ prescriptions in VAPORHCS community-based outpatient clinic (CBOC) settings.

Methods

The VAPORHCS includes 10 CBOCs across Oregon and southern Washington, serving ~95,000 unique veterans with ~900,000 outpatient visits annually. The FQ patient safety initiative, implemented as a new order screen embedded in the EHR, required provider documentation of (1) antibiotic indication, (2) patient education of antibiotic risks, and (3) medication reconciliation to prescribe FQs (Fig. 1). The primary-care chief educated CBOC leadership, who in turn notified providers of the new menu. Messaging focused on the fulfillment of a mandated patient safety initiative.

Fig. 1

The pop-up image of the EHR-embedded check list upon prescribing oral fluoroquinolones in Veterans Affairs Portland Health Care System. Note. EHR, electronic health record.

From January 1, 2013, to April 30, 2015, we retrospectively extracted and analyzed data for all FQ prescriptions dispensed and filled at all CBOCs in VAPORHCS including 78 weeks before and 43 weeks after implementation of the FQ safety initiative. We obtained data from 2 prescription datasets: (1) the VA pharmacy database, which contains all medications prescribed during regular business hours through the EHR, and (2) the contract pharmacy claims database (Heritage Health Solutions, Flower Mound, TX), which includes prescriptions ordered during nonbusiness hours through alternative methods such as paper-based or phone prescription without using the EHR. We excluded prescriptions with durations <4 days (to exclude prophylactic use such as before urologic procedures) and >21 days (to exclude chronic use such as osteomyelitis treatment). We considered the prescriptions ordered through the EHR as being exposed to the FQ safety initiative directly, and we defined these as a “direct effect” group. The prescriptions ordered through the contract pharmacy (and not through the FQ order menu) were defined as the “indirect effect” group. We labeled these groups as such because all VA providers overlapped and were aware of this patient safety initiative. We obtained the number of all clinical visits (excluding vaccination-only clinic visits during influenza vaccine campaign) in CBOCs during the study period as the denominator. We defined the weekly FQ prescription rate as the number of weekly FQ prescriptions divided by the number of weekly CBOC visits.

We analyzed the effect of the initiative via quasi-experimental interrupted time-series analysis. We used Poisson regression model (count time-series model) to account for baseline trend, intercept change, and change in trend. Month of the year was also included as a categorical variable to account for seasonality. The model’s outcome variable was the number of weekly FQ prescriptions, and the number of weekly clinic visits was included as an offset variable. Impacts of included variables were expressed as incidence rate ratios (IRRs), and corresponding 95% confidence intervals (CIs) were calculated. Residuals and leverage plots were examined to assess model appropriateness. As a nonequivalent dependent control group, we also analyzed the non-FQ antibiotic prescription rate in a similar manner. The VAPORHCS Institutional Review Board approved this study.

Results

In total, 641,778 CBOC visits occurred during the study period and were included; the mean number of visits per week was 5,304 (SD ±709.9). The direct and indirect effect groups filled 1,138 and 853 FQ prescriptions, respectively, and the mean weekly numbers of filled prescriptions (±SD) were 7.0 (±3.5) and 9.4 (±4.1), respectively.

Both the direct and indirect effect groups experienced a statistically significant reduction in the weekly FQ prescription rate immediately after the initiative was implemented; however, the decreased rate trend in either group did not persist (Fig. 2, A and B). Specifically, during the preimplementation period, the weekly FQ prescription rate declined 0.4% per week (IRR, 0.996; 95% CI, 0.993–0.999; P = .016) in the direct-effect group and ~0.4% per week (IRR, 0.996; 95% CI, 0.993–1.000; P = .044) in the indirect-effect group. Immediately after the initiative was implemented, statistically significant reductions in the FQ prescriptions were observed: a ~62% per week reduction in direct-effect group (IRR, 0.383; 95% CI, 0.271–0.538; P < .001) and a ~62% per week reduction in the indirect-effect group (IRR, 0.377; 95% CI, 0.254–0.557; P < .001). However, the FQ prescription rates in both groups thereafter reverted to baseline prescription rates over time via ~1.9% per week (IRR to baseline trend, 1.023; 95% CI, 1.011–1.035; P < .001) and 2.1% per week (IRR to baseline trend, 1.025; 95% CI, 1.011–1.039; P < .001) in the direct- and indirect-effect groups, respectively. For the non-FQ prescription rate (Fig. 2, C and D), no intercept change was observed in either group immediately after the intervention, and we observed elevated trends thereafter.

Fig. 2

Weekly FQ and non-FQ prescription rate—All CBOCs within the Veterans Affairs Portland Healthcare System, January 1, 2013, through April 30, 2015. (A) FQ prescription rate in direct effect group, (B) FQ prescription rate in indirect effect group, (C) non-FQ prescription rate in direct effect group, (D) non-FQ prescription rate in indirect effect group. Vertical dotted lines represent the week when the FQ patient safety initiative was implemented. Note. CBOC, community-based outpatient clinic; FQ, fluoroquinolone.

Discussion

We found that the FQ patient safety initiative implemented in CBOCs via the EHR initially significantly reduced the FQ prescription rate without affecting the rate of non-FQ antibiotic prescriptions, but this early FQ prescription rate reduction was not sustained. Our study is distinct from other EHR-based interventionsReference Meeker, Linder and Fox 6 , Reference Persell, Doctor and Friedberg 7 because it was driven not by an antibiotic stewardship team but primarily by patient safety as part of a medication management initiative focused on FQ prescribing, 5 which required components of traditional stewardship. For instance, the provider was required to justify the FQ indication alongside additional patient safety aspects, including medication reconciliation.

An immediate FQ prescription drop was observed in both groups, and most likely indicated a spillover effect on the indirect-effect group. Therefore, some component of the intervention influenced practices in the indirect-effect group beyond the EHR checklist itself.Reference Persell, Doctor and Friedberg 7

We suspect that the initial success was not sustained because the initiative was not coupled with ongoing training on this menu, ongoing education on rational FQ use and recommended alternatives, or performance feedback and audit. These approaches have been shown to enhance sustainability.Reference Gerber, Prasad and Fiks 8 Alternatively, the postintervention trend may have been unsustained due to unmeasured external factors such as number and type of clinic visits, as we observed similar postintervention increased prescription rates in both FQ and non-FQ groups.

Our study has limitations. We only observed weekly prescriptions for 1 year after the initiative was implemented; thus, we were unable to determine whether the FQ prescription rate reverted completely to the preimplementation period. The overall study period, however, was long enough to account for relevant factors such as seasonality.Reference Suda, Hicks, Roberts, Hunkler and Taylor 9 A qualitative study to evaluate how and why providers and patients responded to this initiative and to analyze barriers to sustainability, such as alert fatigue and EHR workaround,Reference Ancker, Edwards and Nosal 10 was not performed but would be useful to inform future interventions.

In conclusion, we found that this FQ patient safety initiative was associated with a significant initial but unsustained reduction of FQ prescriptions over time, and overall, it aligned with goals of outpatient antibiotic stewardship. Further study should investigate ways to create strategies that sustain such initiatives in the outpatient setting.

Financial support

No financial support was provided relevant to this article.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

Acknowledgments

We thank Mike Alperin, MD, MBA, for his feedback on the study concept. We also thank Alyssa Meyer, MBA, at DHSM, Alison Mosely, BA, CPhT, at Heritage Health Solutions, and Brian Wilcox, PharmD, at VAPORHCS for their support in providing prescription data and clinic visit data. The research represented in this article is that of the authors and does not reflect the official policy of the Veterans Affairs.

Footnotes

a

Present affiliation: K.J. is now affiliated with Infectious Disease Control Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.

PREVIOUS PRESENTATION: Part of this study was presented at The Society for Healthcare Epidemiology of America Spring 2016 conference in Atlanta, Georgia, on May 20, 2016.

Cite this article: Jindai K, et al. (2018). Improving fluoroquinolone use in the outpatient setting using a patient safety initiative. Infection Control & Hospital Epidemiology 2018, 39, 1108–1111. doi: 10.1017/ice.2018.169

References

1. Kabbani, S, Hersh, AL, Shapiro, DJ, Fleming-Dutra, KE, Pavia, AT, Hicks, LA. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis 2018;67:134–136.Google Scholar
2. Stewardson, AJ, Vervoort, J, Adriaenssens, N, et al. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study. Clin Microbiol Infect 2018. doi: 10.1016/j.cmi.2017.12.026.Google Scholar
3. Dingle, KE, Didelot, X, Quan, TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 2017;17:411–421.Google Scholar
4. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm. Published 2016. Accessed January 30, 2018.Google Scholar
5. Department of Veterans Affairs Office of Inspector General. Community Based outpatient clinic and primary care clinic reviews at Portland VA Medical Center Portland, Oregon. Department of Veterans Affairs website. http://www.va.gov/oig/pubs/VAOIG-13-03417-34.pdf. Published 2014. Accessed April 1, 2017.Google Scholar
6. Meeker, D, Linder, JA, Fox, CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA 2016;315:562–570.Google Scholar
7. Persell, SD, Doctor, JN, Friedberg, MW, et al. Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trial. BMC Infect Dis 2016;16:373.Google Scholar
8. Gerber, JS, Prasad, PA, Fiks, AG, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. JAMA 2013;309:2345–2352.Google Scholar
9. Suda, KJ, Hicks, LA, Roberts, RM, Hunkler, RJ, Taylor, TH. Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother 2014;58:2763–2766.Google Scholar
10. Ancker, JS, Edwards, A, Nosal, S, et al. Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Informat Decis Making 2017;17:36.Google Scholar
Figure 0

Fig. 1The pop-up image of the EHR-embedded check list upon prescribing oral fluoroquinolones in Veterans Affairs Portland Health Care System. Note. EHR, electronic health record.

Figure 1

Fig. 2Weekly FQ and non-FQ prescription rate—All CBOCs within the Veterans Affairs Portland Healthcare System, January 1, 2013, through April 30, 2015. (A) FQ prescription rate in direct effect group, (B) FQ prescription rate in indirect effect group, (C) non-FQ prescription rate in direct effect group, (D) non-FQ prescription rate in indirect effect group. Vertical dotted lines represent the week when the FQ patient safety initiative was implemented. Note. CBOC, community-based outpatient clinic; FQ, fluoroquinolone.